An official decision on whether to approve Orkambi is expected from the FDA by July 5 and the agency does not have to adhere to the panel's recommendation, but the vote of confidence has nonetheless raised the company's profile in trading today. The advisory committee unanimously declared that Orkambi is safe with one board member saying that, "The risks are small, or modest, and are all manageable with appropriate monitoring."